The Main Challenges in Systemic Lupus Erythematosus: Where Do We Stand?
Systemic lupus erythematosus (SLE) is an immune-mediated multi-systemic disease characterized by a wide variability of clinical manifestations and a course frequently subject to unpredictable flares. Despite significant advances in the understanding of the pathophysiology and optimization of medical...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-01-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/10/2/243 |
id |
doaj-573882fad53f4f929cdcc59653f3bb15 |
---|---|
record_format |
Article |
spelling |
doaj-573882fad53f4f929cdcc59653f3bb152021-01-12T00:04:33ZengMDPI AGJournal of Clinical Medicine2077-03832021-01-011024324310.3390/jcm10020243The Main Challenges in Systemic Lupus Erythematosus: Where Do We Stand?Matteo Piga0Laurent Arnaud1Rheumatology Unit, AOU University Clinic and University of Cagliari, 09042 Cagliari, ItalyService de Rhumatologie, Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, 67000 Strasbourg, FranceSystemic lupus erythematosus (SLE) is an immune-mediated multi-systemic disease characterized by a wide variability of clinical manifestations and a course frequently subject to unpredictable flares. Despite significant advances in the understanding of the pathophysiology and optimization of medical care, patients with SLE still have significant mortality and carry a risk of progressive organ damage accrual and reduced health-related quality of life. New tools allow earlier classification of SLE, whereas tailored early intervention and treatment strategies targeted to clinical remission or low disease activity could offer the opportunity to reduce damage, thus improving long-term outcomes. Nevertheless, the early diagnosis of SLE is still an unmet need for many patients. Further disentangling the SLE susceptibility and complex pathogenesis will allow to identify more accurate biomarkers and implement new ways to measure disease activity. This could represent a major step forward to find new trials modalities for developing new drugs, optimizing the use of currently available therapeutics and minimizing glucocorticoids. Preventing and treating comorbidities in SLE, improving the management of hard-to-treat manifestations including management of SLE during pregnancy are among the remaining major unmet needs. This review provides insights and a research agenda for the main challenges in SLE.https://www.mdpi.com/2077-0383/10/2/243systemic lupus erythematosusreviewdisease activitydamageglucocorticoids |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Matteo Piga Laurent Arnaud |
spellingShingle |
Matteo Piga Laurent Arnaud The Main Challenges in Systemic Lupus Erythematosus: Where Do We Stand? Journal of Clinical Medicine systemic lupus erythematosus review disease activity damage glucocorticoids |
author_facet |
Matteo Piga Laurent Arnaud |
author_sort |
Matteo Piga |
title |
The Main Challenges in Systemic Lupus Erythematosus: Where Do We Stand? |
title_short |
The Main Challenges in Systemic Lupus Erythematosus: Where Do We Stand? |
title_full |
The Main Challenges in Systemic Lupus Erythematosus: Where Do We Stand? |
title_fullStr |
The Main Challenges in Systemic Lupus Erythematosus: Where Do We Stand? |
title_full_unstemmed |
The Main Challenges in Systemic Lupus Erythematosus: Where Do We Stand? |
title_sort |
main challenges in systemic lupus erythematosus: where do we stand? |
publisher |
MDPI AG |
series |
Journal of Clinical Medicine |
issn |
2077-0383 |
publishDate |
2021-01-01 |
description |
Systemic lupus erythematosus (SLE) is an immune-mediated multi-systemic disease characterized by a wide variability of clinical manifestations and a course frequently subject to unpredictable flares. Despite significant advances in the understanding of the pathophysiology and optimization of medical care, patients with SLE still have significant mortality and carry a risk of progressive organ damage accrual and reduced health-related quality of life. New tools allow earlier classification of SLE, whereas tailored early intervention and treatment strategies targeted to clinical remission or low disease activity could offer the opportunity to reduce damage, thus improving long-term outcomes. Nevertheless, the early diagnosis of SLE is still an unmet need for many patients. Further disentangling the SLE susceptibility and complex pathogenesis will allow to identify more accurate biomarkers and implement new ways to measure disease activity. This could represent a major step forward to find new trials modalities for developing new drugs, optimizing the use of currently available therapeutics and minimizing glucocorticoids. Preventing and treating comorbidities in SLE, improving the management of hard-to-treat manifestations including management of SLE during pregnancy are among the remaining major unmet needs. This review provides insights and a research agenda for the main challenges in SLE. |
topic |
systemic lupus erythematosus review disease activity damage glucocorticoids |
url |
https://www.mdpi.com/2077-0383/10/2/243 |
work_keys_str_mv |
AT matteopiga themainchallengesinsystemiclupuserythematosuswheredowestand AT laurentarnaud themainchallengesinsystemiclupuserythematosuswheredowestand AT matteopiga mainchallengesinsystemiclupuserythematosuswheredowestand AT laurentarnaud mainchallengesinsystemiclupuserythematosuswheredowestand |
_version_ |
1724340895083397120 |